Evidence map›Paper›PMID 33332471›Full record

ArticlePloS one2020

The contemporary trend in worsening prognosis of pancreatic acinar cell carcinoma: A population-based study.

Nie Duorui, Bin Shi, Tao Zhang, Chuyao Chen, Chongkai Fang, Zhijun Yue, Peng Wu, Zhiming Wu, Xuewu Huang, Meng Li

Abstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Acinar cell carcinoma of the pancreas: can CT and MR features predict survival?Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Article
  4. Rare tumours of the pancreas: monocentric study.Journal of cancer research and clinical oncology · 2024
    Article
  5. Review
  6. Review
  7. Pathologic Features of Primary Pancreatic Malignancies.Cancer treatment and research · 2024
    Review
  8. Article
  9. Article
  10. Pancreatic acinar cell carcinoma: A comprehensive review.World journal of gastroenterology · 2022
    Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nie DuoruiFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.ORCID 0000-0003-3412-1196
Bin ShiFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Tao ZhangFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Chuyao ChenFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Chongkai FangFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Zhijun YueFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Peng WuFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Zhiming WuFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Xuewu HuangCancer center, Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital, Guangzhou, Guangdong, China.
Meng LiDepartment of Oncology, Shenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary acinar cell carcinoma (ACC) is a rare exocrine tumor of the pancreas with unclear clinical characteristics. Our goal was to determine the incidence and update the clinical characteristics and outcomes of ACC.

methodsThrough the Surveillance, Epidemiology, and End Results (SEER) database, we identified 252 patients with the latest diagnosis of ACC (2004-2016). The age-adjusted incidence (AAI) was calculated using the SEER*Stat Software version 8.3.6. The Kaplan-Meier method was used to draw survival curves and differences among them were compared by the log-rank test. Cox proportional hazards models were used to evaluate factors that had independent predictive effects on the overall survival.

resultsThe AAI of pancreatic ACC was on the rise with the mean age at diagnosis of 63.79±14.79 years. Most patients (15.9%) had poorer differentiated tumors. The patients presented with distant stage were 54.4% compared with 53.1% between 1988 and 2003. The 1-, 2-, and 5-years survival rates for pancreatic ACC patients were 53.5%, 34.6%,17.5%, respectively (compared with 78.5%, 67.0%, and 42.8%, between 1988 and 2003). The multivariate COX analysis showed that the patient's age, surgery, chemotherapy, and summary stage, but not marital status were independent prognosis factors for ACC.

conclusionsPancreatic ACC is a highly malignant tumor with an increasing incidence in recent years. The rate of distant metastasis is increasing and the survival rate is worse than in the past, suggesting that it may require more aggressive treatment and follow-up. Surgery, radiotherapy, and chemotherapy are all effective treatments, but prospective studies are still needed to verify them.

Indexed as

AdolescentAdultAgedAged, 80 and overAge FactorsCarcinoma, Acinar CellChildChild, PreschoolFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPancreatic NeoplasmsPrognosisProportional Hazards Models

Identifiers

PMID33332471
PMCPMC7746196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.